Stocks Health care TRVI
NASDAQ · Health careTrevi Therapeutics, Inc. (TRVI)
It posted a net loss of $60.8M. In fiscal 2025 capital spending exceeded operating cash flow by $42.1M. At September 30, 2026 it held $27.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Trevi Therapeutics, Inc.
- Net worth
- Trevi Therapeutics, Inc. has a market value (market cap) of $2.1B at the latest share price, and shareholders' equity of $302.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $42.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Trevi Therapeutics, Inc.'s next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Trevi Therapeutics, Inc. does
Trevi Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRVI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$42.8M | -$0.32 | -$42.1M |
| 2024 | n/a | -$47.9M | -$0.47 | -$38.3M |
| 2023 | n/a | -$29.1M | -$0.29 | -$31.8M |
| 2022 | n/a | -$29.2M | -$0.45 | -$28.3M |
| 2021 | n/a | -$33.9M | -$1.49 | n/a |
| 2020 | n/a | -$32.8M | -$1.81 | -$29M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Trevi Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- August 6, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- June 4, 2026
- May 7, 2026Activist stake changed SCHEDULE 13D/A
- May 6, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Trevi Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $595.8K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Heffernan Michael ThomasDirector | Exercised options | 18,421 | $56K |
| September 15, 2026 | Heffernan Michael ThomasDirector | Soldpre-planned (10b5-1) | 18,321 | $276.5K |
| September 15, 2026 | Heffernan Michael ThomasDirector | Soldpre-planned (10b5-1) | 100 | $1.6K |
| September 15, 2026 | Heffernan Michael ThomasDirector | Exercised options | 21,052 | $70.1K |
| September 15, 2026 | Heffernan Michael ThomasDirector | Soldpre-planned (10b5-1) | 20,952 | $316.2K |
| September 15, 2026 | Heffernan Michael ThomasDirector | Soldpre-planned (10b5-1) | 100 | $1.6K |
| December 2, 2025 | Galletta ChristopherSee Remarks | Exercised options | 4,225 | $2.2K |
Who owns TRVI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| New Enterprise Associates 16, L.P.13D, may seek influence with 12 related filers | 10.5% | May 7, 2026 |
| Fmr LLC13G, passive with 1 related filers | 8.8% | August 6, 2026 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 13 related filers | 7% | November 14, 2025 |
| BlackRock, Inc.13G, passive | 6.9% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 218 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| NEA Management Company, LLC | 13,222,228 | 0 |
| Fmr LLC | 12,562,839 | +4,524,778 |
| BlackRock, Inc. | 11,155,026 | +914,840 |
| Frazier Life Sciences Management, L.P. | 9,939,447 | -100 |
| Wellington Management Group Llp | 5,684,592 | +495,504 |
| Vanguard Capital Management LLC | 5,530,675 | +552,108 |
| Vivo Capital, LLC | 5,094,668 | 0 |
| Woodline Partners LP | 4,081,333 | +3,080,551 |
| Vestal Point Capital, LP | 3,100,000 | +933,496 |
| Mpm Bioimpact LLC | 3,073,577 | -224,853 |
| Frontier Capital Management Co LLC | 3,070,740 | +1,076,448 |
| Assenagon Asset Management S.A. | 3,050,628 | new |
| State Street Corp | 3,027,315 | +362,002 |
| Geode Capital Management, LLC | 2,928,068 | +149,837 |
| Marshall Wace, Llp | 2,674,137 | -1,291,882 |
| Eventide Asset Management, LLC | 2,660,000 | +37,694 |
| Rubric Capital Management LP | 2,504,513 | -1,207,860 |
| Artia Global Partners LP | 2,210,852 | +197,250 |
| Acorn Capital Advisors, LLC | 2,144,844 | 0 |
| First Light Asset Management, LLC | 2,097,215 | new |
Insiders
2 insiders reported holding 32,446 shares in total, about $484.4K at the last price.
| Holder | Shares |
|---|---|
| Galletta ChristopherSee Remarks | 26,095 |
| Heffernan Michael ThomasDirector | 6,351 |
Questions about TRVI
What does Trevi Therapeutics, Inc. do?
Trevi Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TRVI. Its shares trade on NASDAQ under the ticker TRVI.
What is Trevi Therapeutics, Inc.'s net worth?
Trevi Therapeutics, Inc. has a market value (market cap) of $2.1B at the latest share price, and shareholders' equity of $302.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Trevi Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $60.8M.
When did Trevi Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Trevi Therapeutics, Inc.'s next earnings report?
Trevi Therapeutics, Inc.'s next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TRVI with
Follow TRVI
Get an email when Trevi Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Trevi Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.